ARVs: the next generation. Going boldly together to new frontiers of HIV treatment
- PMID: 25745115
- PMCID: PMC4356270
- DOI: 10.9745/GHSP-D-14-00243
ARVs: the next generation. Going boldly together to new frontiers of HIV treatment
Abstract
New antiretrovirals (ARVs), particularly the potentially “game-changing” ARV dolutegravir, offer major potential to meet the compelling need for simpler and better HIV treatment for tens of millions of people in the coming decade. Advantages include substantially lower manufacturing cost, fewer side effects, and less risk of resistance. But key obstacles must be addressed in order to develop and introduce new ARVs in specific combinations optimized for the needs of low- and middle-income countries. Strong leadership will be essential from the global health community to nurture more focused collaboration between the private and public sectors.
References
-
- Joint United Nations Programme on HIV/AIDS (UNAIDS). Fast-track: ending the AIDS epidemic by 2030. Geneva: UNAIDS; 2014. Available from: http://www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014repo...
-
- UNAIDS. Fact sheet. Geneva: UNAIDS; 2014. Available from: http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/factsheet
-
- Supply Chain Management System (SCMS) [Internet]. Arlington (VA): SCMS; E-catalog: ARVs; updated Nov 2014 [cited 2015 Jan 13]; [about 4 screens]. Available from: http://scms.pfscm.org/scms/ecatalog/arvs
-
- Llibre JM, Pulido F, García F, García Deltoro M, Blanco JL, Delgado R. Genetic barrier to resistance for dolutegravir. AIDS Rev. 2014;17(1). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical